Imagine cancer as a weed where some seeds are invisible to current weedkillers, allowing the plant to grow back. This technology creates a 'training manual' for the immune system using modified stem cells to help the body spot and kill those hidden seeds. It essentially teaches the immune system to recognize the most stubborn parts of a tumor to prevent it from returning.
Current immunotherapies fail in 70% of patients because they cannot target cancer stem cells, which lead to tumor recurrence and metastasis.
A mutated iPSC-based vaccine (iPVAC Mut) and a predictive in vitro immunogenicity bioassay for patient stratification.
If you are a drug developer dealing with the 30% response rate of current checkpoint inhibitors — this project developed iPVAC Mut that targets cancer stem cells to prevent tumor relapse and metastatic spread.
If you are a diagnostic lab dealing with unpredictable patient responses to immunotherapy — this project developed a predictive in vitro immunogenicity bioassay that enables patient stratification and immune monitoring.
If you are a discovery firm dealing with a lack of first-in-class targets for aggressive cancers — this project developed an iPSC based discovery platform to identify new cancer targets and immunotherapy pipelines.
Based on available project data, specific pricing or cost structures are not provided; however, the project received an EU contribution of EUR 1,782,000 for development.
Yes, the project describes the therapy as an allogenic, off-the-shelf product that is highly scalable using a versatile technology.
The project aims to strengthen scientific data to lead to new patents and open access publications, utilizing proprietary technology to generate high mutational loads.
It is designed to address the failures of current therapies, such as the 70% of patients who do not respond optimally to immune checkpoint inhibitors, by targeting resistant cancer stem cells.
The project period runs from 2022-10-01 to 2025-09-30, with the goal of preparing the technology for clinical development.
The project is led by a single partner, IPSIRIUS, which is a French SME and spinoff from INSERM and Paris Saclay University. With a 100% industry ratio, the project is streamlined for commercial translation rather than academic research, focusing on transforming a proprietary iPSC platform into a scalable product.
Contact IPSIRIUS in France
Contact us to explore licensing opportunities for the iPVAC Mut platform.
